Clinical characteristics stratified by the timing of selective immunosuppressive therapy initiation (SIT)
| Covariate | ≤ 10 days of onsetN = 44 | > 10 days of onsetN = 40 | P |
|---|---|---|---|
| ICI type, No. (%) | 0.687 | ||
| Anti-CTLA-4 monotherapy | 11 (25) | 10 (25) | |
| Anti-PD-1/L1 monotherapy | 19 (43) | 14 (35) | |
| Combination | 14 (32) | 16 (40) | |
| Diarrhea grade, No. (%) | 0.668 | ||
| 1–2 | 8 (18) | 6 (15) | |
| 3 | 28 (64) | 29 (73) | |
| 4 | 8 (18) | 5 (13) | |
| Colitis grade, No. (%) | 0.603 | ||
| 1–2 | 24 (56) | 22 (55) | |
| 3 | 16 (37) | 17 (43) | |
| 4 | 3 (7) | 1 (3) | |
| Endoscopic features, No. (%) | 0.739 | ||
| Ulcer | 13 (42) | 17 (52) | |
| Non-ulcerative inflammation | 12 (39) | 11 (33) | |
| Normal | 6 (19) | 5 (15) | |
| High-risk endoscopic features initially, No. (%)a | 17 (55) | 23 (70) | 0.302 |
| Overall duration of steroids, mean days (SD) | 64 (38) | 82 (51) | 0.092 |
| Duration of hospitalization, mean days (SD) | 10 (8) | 12 (8) | 0.321 |
| Duration of symptoms, mean days (SD) | 25 (32) | 50 (40) | 0.002 |
| Follow-up duration, mean months (SD) | 5 (3) | 4 (3) | 0.875 |
| Number of steroids tapering attempts, median (IQR) | 1 (1–4) | 2 (1–4) | < 0.001 |
| Multiple hospitalization, No. (%) | 13 (30) | 22 (55) | 0.026 |
| Failed steroid tapering after SIT, No. (%)b | 9 (23) | 19 (49) | 0.033 |
| Recurrent IMC, No. (%) | 8 (18) | 8 (20) | 1.000 |
| Infectious adverse events, No. (%) | 16 (36) | 9 (23) | 0.233 |
aHigh-risk features are ulcers deeper than 2 mm or wider than 1 cm, and extensive endoscopic inflammation involving the colon proximal to the splenic flexure
bAvailable for the 79 patients who received steroids
Abbreviation: SIT, selective immunosuppressive therapy